SI1468697T1 - Sestavki, ki vsebujejo piperacilin in tazobaktam,uporabni za injekcije - Google Patents

Sestavki, ki vsebujejo piperacilin in tazobaktam,uporabni za injekcije

Info

Publication number
SI1468697T1
SI1468697T1 SI200430609T SI200430609T SI1468697T1 SI 1468697 T1 SI1468697 T1 SI 1468697T1 SI 200430609 T SI200430609 T SI 200430609T SI 200430609 T SI200430609 T SI 200430609T SI 1468697 T1 SI1468697 T1 SI 1468697T1
Authority
SI
Slovenia
Prior art keywords
injection
compositions containing
tazobactam
useful
containing piperacillin
Prior art date
Application number
SI200430609T
Other languages
English (en)
Slovenian (sl)
Inventor
Jonathan Marc Cohen
Syed Muzafar Shah
Christian Luther Ofslager
Mahdi Bakir Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1468697(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SI1468697T1 publication Critical patent/SI1468697T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200430609T 2003-04-14 2004-04-06 Sestavki, ki vsebujejo piperacilin in tazobaktam,uporabni za injekcije SI1468697T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46280803P 2003-04-14 2003-04-14
EP04076075A EP1468697B1 (fr) 2003-04-14 2004-04-06 Compositions injectables contenant de la piperacilline et du tazobactame

Publications (1)

Publication Number Publication Date
SI1468697T1 true SI1468697T1 (sl) 2008-04-30

Family

ID=32326726

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430609T SI1468697T1 (sl) 2003-04-14 2004-04-06 Sestavki, ki vsebujejo piperacilin in tazobaktam,uporabni za injekcije

Country Status (35)

Country Link
US (3) US7498312B2 (fr)
EP (1) EP1468697B1 (fr)
JP (1) JP4644659B2 (fr)
KR (1) KR100824554B1 (fr)
CN (1) CN1802179B (fr)
AR (1) AR043863A1 (fr)
AT (1) ATE381947T1 (fr)
AU (1) AU2004229407B2 (fr)
BR (1) BRPI0409450B8 (fr)
CA (1) CA2464258C (fr)
CH (1) CH695185A9 (fr)
CL (1) CL2004000782A1 (fr)
CO (1) CO5700796A2 (fr)
CR (2) CR8035A (fr)
CY (1) CY1108064T1 (fr)
DE (1) DE602004010862T2 (fr)
DK (1) DK1468697T3 (fr)
EC (1) ECSP056100A (fr)
ES (1) ES2298672T3 (fr)
FR (1) FR2853547B1 (fr)
GB (1) GB2400557B (fr)
HK (1) HK1069775A1 (fr)
IL (1) IL171337A (fr)
MX (1) MXPA05010996A (fr)
MY (1) MY139099A (fr)
NO (1) NO20054789L (fr)
NZ (1) NZ543005A (fr)
PL (1) PL1468697T3 (fr)
PT (1) PT1468697E (fr)
RU (2) RU2322980C2 (fr)
SA (1) SA04250119B1 (fr)
SI (1) SI1468697T1 (fr)
TW (1) TWI308069B (fr)
WO (1) WO2004091666A1 (fr)
ZA (1) ZA200508315B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004057959A2 (fr) 2002-12-20 2004-07-15 Generipharm, Inc. Injection intracutanee
PL1468697T3 (pl) * 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań
CA2581303A1 (fr) * 2004-10-14 2006-04-27 Wyeth Preparations contenant de la piperacilline, du tazobactam et un acide aminocarboxylique dilues dans du lactate de sodium
RS51506B (en) * 2004-12-02 2011-06-30 Venus Remedies Limited H. O&R&D. BETA-LACTAMASE INTERFERENCE MIXTURES OF MEDIUM RESISTANCE TO ANTIBIOTICS USING BETA-LACTAMASE INHIBITORS USED FOR INJECTION
ES2284318B1 (es) * 2005-04-13 2008-11-01 Labiana Development, S.L. Procedimiento de obtencion de una mezcla en polvo de una sal sodica de piperaciclina y tazobactama, util para su administracion por via inyectable.
ITMI20051630A1 (it) 2005-09-02 2007-03-03 Acs Dobfar Spa Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
CN102441169A (zh) * 2006-08-25 2012-05-09 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN102210679B (zh) * 2006-08-25 2013-03-13 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN1927201B (zh) * 2006-08-25 2011-06-01 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN101265263B (zh) * 2008-05-12 2010-06-02 海南百那医药发展有限公司 哌拉西林钠他唑巴坦钠复方注射剂的生产方法
WO2010013640A1 (fr) * 2008-07-28 2010-02-04 Yamaguchi Keizo Potentialisateur d'efficacité thérapeutique sur une maladie infectieuse
JP5852316B2 (ja) * 2010-03-30 2016-02-03 富山化学工業株式会社 ピペラシリン含有懸濁液の製造法
WO2012012460A1 (fr) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Formulations de glucagon stables pour le traitement de l'hypoglycémie
JP5961177B2 (ja) 2010-11-25 2016-08-02 アレクラ セラピューティクス ゲーエムベーハー 化合物及びその使用
EA028572B1 (ru) 2011-03-10 2017-12-29 Ксерис Фармасьютикалс, Инк. Стабильная композиция для парентеральной инъекции и способы ее получения и использования
AU2012332556B2 (en) 2011-10-31 2016-05-26 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
EP3431092A1 (fr) 2012-03-26 2019-01-23 Santen Pharmaceutical Co., Ltd. Solution ophtalmique comprenant du diquafosol
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
KR101816798B1 (ko) * 2012-10-19 2018-01-10 주식회사유한양행 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274994A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Stabilizing ceftolozane
US20140274996A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Tazobactam and ceftolozane antibiotic compositions
EP3043797B1 (fr) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Traitement d'infections au moyen de ceftolozane/tazobactam chez des sujets ayant une fonction rénale altérée
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
JP6982495B2 (ja) 2014-08-06 2021-12-17 ゼリス ファーマシューティカルズ インコーポレイテッド ペーストの皮内および/または皮下注射のためのシリンジ、キット、および方法
JPWO2016056527A1 (ja) * 2014-10-08 2017-07-20 沢井製薬株式会社 凍結乾燥製剤の製造方法
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
EP3268001A1 (fr) * 2016-03-31 2018-01-17 Wockhardt Limited Compositions anti-bactériennes
WO2018025248A1 (fr) * 2016-08-05 2018-02-08 Jodas Expoim Private Limited Injection d'edta et son procédé de fabrication.
EP4378463A2 (fr) 2017-06-02 2024-06-05 Xeris Pharmaceuticals, Inc. Composition des petites molecules resistante a la precipitation
US11110054B2 (en) * 2018-05-09 2021-09-07 Slayback Pharma Llc Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
CN112618486B (zh) * 2020-12-24 2023-07-18 浙江昂利康制药股份有限公司 一种注射用混悬油剂及其制备方法
CN113209030B (zh) * 2021-04-27 2023-04-25 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477452A (en) 1981-03-26 1984-10-16 American Cyanamid Company Composition of matter comprising a lyophilized preparation of a penicillin derivative
US4534977A (en) 1981-03-26 1985-08-13 American Cyanamid Company Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
US4562073A (en) 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US5763480A (en) * 1994-02-14 1998-06-09 The Jewish Hospital Of St. Louis Inhibitors of cell-medicated disorders
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6207661B1 (en) * 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection
EP1499341A4 (fr) * 2002-04-18 2010-10-27 Univ Iowa Res Found Procede pour inhiber et traiter de films biologiques au moyen de chelateurs metalliques
PL1468697T3 (pl) * 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
WO2004098643A1 (fr) * 2003-04-14 2004-11-18 Wyeth Holdings Corporation Compositions d'injection contenant piperacilline et tazobactame

Also Published As

Publication number Publication date
DE602004010862T2 (de) 2009-01-02
KR100824554B1 (ko) 2008-04-24
ES2298672T3 (es) 2008-05-16
TW200503758A (en) 2005-02-01
TWI308069B (en) 2009-04-01
NO20054789L (no) 2005-12-13
CO5700796A2 (es) 2006-11-30
SA04250119B1 (ar) 2008-03-30
ATE381947T1 (de) 2008-01-15
AR043863A1 (es) 2005-08-17
RU2322980C2 (ru) 2008-04-27
JP2006523695A (ja) 2006-10-19
NO20054789D0 (no) 2005-10-18
FR2853547B1 (fr) 2006-08-04
GB2400557A (en) 2004-10-20
CH695185A9 (fr) 2006-02-28
AU2004229407A1 (en) 2004-10-28
CN1802179A (zh) 2006-07-12
RU2007142454A (ru) 2009-05-27
US20060234995A1 (en) 2006-10-19
ECSP056100A (es) 2006-03-01
US7498312B2 (en) 2009-03-03
CN1802179B (zh) 2011-09-14
CY1108064T1 (el) 2014-02-12
HK1069775A1 (en) 2005-06-03
ZA200508315B (en) 2008-04-30
US20110166091A1 (en) 2011-07-07
CR9792A (es) 2008-09-23
KR20060014375A (ko) 2006-02-15
MY139099A (en) 2009-08-28
WO2004091666A1 (fr) 2004-10-28
AU2004229407B2 (en) 2010-04-22
CR8035A (es) 2006-05-30
PL1468697T3 (pl) 2008-05-30
FR2853547A1 (fr) 2004-10-15
GB0407853D0 (en) 2004-05-12
BRPI0409450B1 (pt) 2016-07-12
EP1468697B1 (fr) 2007-12-26
RU2005135135A (ru) 2006-06-10
PT1468697E (pt) 2008-03-05
IL171337A (en) 2011-03-31
CA2464258A1 (fr) 2004-10-14
EP1468697A1 (fr) 2004-10-20
US8133883B2 (en) 2012-03-13
DE602004010862D1 (de) 2008-02-07
NZ543005A (en) 2009-03-31
US20090176720A1 (en) 2009-07-09
US7915229B2 (en) 2011-03-29
CH695185A5 (fr) 2006-01-13
DK1468697T3 (da) 2008-04-14
CA2464258C (fr) 2005-06-07
BRPI0409450B8 (pt) 2021-05-25
BRPI0409450A (pt) 2006-05-02
CL2004000782A1 (es) 2005-03-04
JP4644659B2 (ja) 2011-03-02
WO2004091666A8 (fr) 2005-11-10
GB2400557B (en) 2005-06-15
MXPA05010996A (es) 2005-12-12

Similar Documents

Publication Publication Date Title
GB2400557B (en) Compositions containing piperacillin and tazobactam useful for injection
AU2003230899A1 (en) Compositions containing piperacillin and tazobactam useful for injection
HK1093975A1 (en) Ppar-activating compound and pharmaceutical composition containing same
AP2089A (en) Compositions and methods for combination antiviraltherapy
AU2003220205A8 (en) Ethanol-diesel fuel composition and methods thereof
HK1090639A1 (en) Immunosuppressant compounds and compositions
PT1633336T (pt) Compostos e composições imunossupressores
EP1644367A4 (fr) Compositions et composes immunosuppresseurs
IL197889A (en) Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same
GB0222091D0 (en) Dental compositions and methods
AU2003256805A8 (en) Compounds compositions and methods
AU2003287443A8 (en) Compositions and methods for pain reduction
GB0326520D0 (en) Molluscicidal and anti-barnacle compounds
HK1092711A1 (en) Pharmeceutical composition with improved solubility and fluidity
EP1541139A4 (fr) Composition medicinale renfermant un inhibiteur de nf-kappa b
SG122811A1 (en) Fuel additive composition and fuel composition containing the same
ZA200601232B (en) 3-Aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them
EP1682088A4 (fr) Composition de microemulsion orale comprenant de biphenyldimethyldicarboxylate et de la silybine
GB0304508D0 (en) Antiperspirant actives and compositions
GB0323240D0 (en) Creatine composition and use
SI1661890T1 (sl) Spojina, ki aktivira PPAR, in farmacevtski sestavek, ki jo vsebuje
AU2003220601A8 (en) Synergistic l-methadone compositions and methods of use thereof
GB0325237D0 (en) Composition and use
GB0325239D0 (en) Composition and use
GB0311166D0 (en) Composition and use